贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液的临床研究  被引量:25

Clinical research of intrapleural therapy with bevacizumab plus carboplatin in treatment of malignant pleural effusion caused by non-small cell lung cancer

在线阅读下载全文

作  者:姜敏[1] 迟峰[1] 吴荣[1] 

机构地区:[1]中国医科大学附属盛京医院肿瘤科,辽宁沈阳110022

出  处:《临床肺科杂志》2017年第5期813-816,共4页Journal of Clinical Pulmonary Medicine

摘  要:目的观察分析贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液的疗效和安全性。方法选取我院经病理确诊的52例非小细胞肺癌伴恶性胸腔积液患者,分为试验组及对照组。试验组24例:贝伐珠单抗5mg/kg+生理盐水20m L;卡铂注射液300mg+生理盐水50m L经中心静脉导管胸腔灌注。对照组:单用卡铂,用药剂量及用法同试验组。每7天用药1次,连续给药3次。结果 52例均纳入分析,两组有效率分别为87.5%、60.7%(P<0.05),联合贝伐单抗组高血压、蛋白尿发生率略有升高,重度不良反应较对照组无明显增加。结论贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液,效果良好,安全性高。Objective To assess and analyze the efficacy and safety of intrapleural therapy with bevacizumab plus carboplatin in treatment of malignant pleura] effusion caused by non-small cell lung cancer. Methods 52 NSCLC patients with MPE were divided into two groups: the treatment group (24 cases) and the control group (28 cases). The treatment group was treated with bevaeizumab 5mg/kg, carboplatin 300mg through central venous cathe- ter, and the control group was applied with carboplatin with the same dose. The two groups were both treated once a week, for 3 weeks. Results All 52 patients were included for analysis. The response rate was 87. 5 % and 60. 7% respectively ( P 〈 0. 05). In the bevacizumab group, the incidence of hypertension and proteinuria was slightly high- er, but without any statistical difference. There was no significant difference in severe adverse effect between the two groups. Conclusion Intrapleural therapy with bevacizumab plus carboplatin is effective and safe in treatment of ma- lignant pleural effusion caused by non-small cell lung cancer.

关 键 词:贝伐单抗 卡铂 非小细胞肺癌 胸腔积液 

分 类 号:R734.2[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象